Procalcitonin in Hepatocellular Carcinoma

Ain Shams University42 enrolled

Overview

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatocellular Carcinoma

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. \- Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency. 2. \- Fever more than 38C after 48 hours post intervention. Exclusion Criteria: 1. HCC Patients who does not develop fever after intervention. 2. Proven infection elsewhere (e.g. UTI, chest infection..)

Locations (1)

Tropical medicine department and hepatocellular carcinoma clinic

Cairo, Egypt

Outcomes

Primary Outcomes

Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma

Time frame: 6months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.